Low-dose aspirin in the prevention of miscarriage in women with unexplained or autoimmune-related recurrent miscarriage: effect on prostacyclin and thromboxane A(2) production

被引：0
|
作者：
Tulppala, M
Marttunen, M
SoderstromAnttila, V
Ailus, K
Palosuo, T
Ylikorkala, O
机构：
[1] FAMILY FEDERAT FINLAND,INFERTIL CLIN,HELSINKI,FINLAND
[2] UNIV HELSINKI,CENT HOSP,DEPT OBSTET & GYNECOL,FIN-00290 HELSINKI,FINLAND
[3] NATL PUBL HLTH INST,HELSINKI,FINLAND
来源：
HUMAN REPRODUCTION | 1997年 / 12卷
关键词：
D O I：
暂无
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
引用
收藏
页码：P150 / P150
页数：1
相关论文
共 50 条
  • [41] A RANDOMIZED PLACEBO-CONTROLLED STUDY OF THE EFFECT OF LOW-DOSE ASPIRIN ON PLATELET REACTIVITY AND SERUM THROMBOXANE-B2 PRODUCTION IN NONPREGNANT WOMEN, IN NORMAL-PREGNANCY, AND IN GESTATIONAL HYPERTENSION
    LOUDEN, KA
    PIPKIN, FB
    SYMONDS, EM
    TUOHY, P
    OCALLAGHAN, C
    HEPTINSTALL, S
    FOX, S
    MITCHELL, JRA
    BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 1992, 99 (05): : 371 - 376
  • [42] Effect of low-dose aspirin on the primary prevention of colorectal cancer in patients with type 2 diabetes taking metformin
    Shami, Jessica
    Yan, Vincent Kc
    Wei, Yue
    Wong, Ian
    Chan, EstherW
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 332 - 332
  • [43] Effect of low-dose aspirin intervention on pre-eclampsia prevention in high-risk pregnant women and its impact on postpartum hemorrhage
    Zhang, Fangfang
    Wang, Huijuan
    FRONTIERS IN MEDICINE, 2024, 11
  • [44] Effect of low-dose aspirin on urinary 11-dehydro-thromboxane B2 in the ASCEND (A Study of Cardiovascular Events iN Diabetes) randomized controlled trial
    Parish, Sarah
    Buck, Georgina
    Aung, Theingi
    Mafham, Marion
    Clark, Sarah
    Hill, Michael R.
    Collins, Rory
    Bowman, Louise
    Armitage, Jane
    TRIALS, 2023, 24 (01)
  • [45] Effect of low-dose aspirin on urinary 11-dehydro-thromboxane B2 in the ASCEND (A Study of Cardiovascular Events iN Diabetes) randomized controlled trial
    Sarah Parish
    Georgina Buck
    Theingi Aung
    Marion Mafham
    Sarah Clark
    Michael R. Hill
    Rory Collins
    Louise Bowman
    Jane Armitage
    Trials, 24
  • [46] URINARY-EXCRETION OF THROMBOXANE AND PROSTACYCLIN METABOLITES DURING CHRONIC LOW-DOSE ASPIRIN - EVIDENCE FOR AN EXTRARENAL ORIGIN OF URINARY THROMBOXANE B2 AND 6-KETO-PROSTAGLANDIN F1 ALPHA IN HEALTHY-SUBJECTS
    CHIABRANDO, C
    RIVOLTELLA, L
    MARTELLI, L
    VALZACCHI, S
    FANELLI, R
    BIOCHIMICA ET BIOPHYSICA ACTA, 1992, 1133 (03) : 247 - 254
  • [47] No effect of low-dose aspirin for the prevention of heterotopic bone formation after total hip replacement - A randomized trial of 2,649 patients
    Neal, BC
    Rodgers, A
    Gray, H
    Clark, T
    Beaumonts, DD
    House, T
    Douglas, JE
    Reid, IR
    MacMahon, SW
    ACTA ORTHOPAEDICA SCANDINAVICA, 2000, 71 (02): : 129 - 134
  • [48] NEONATAL PLATELET REACTIVITY AND SERUM THROMBOXANE B-2 PRODUCTION IN WHOLE-BLOOD - THE EFFECT OF MATERNAL LOW-DOSE ASPIRIN AND PLATELET ACTIVATION IN NORMOTENSIVE AND HYPERTENSIVE PREGNANCIES COMPLICATED BY INTRAUTERINE GROWTH-RETARDATION - REPLY
    NORRIS, LA
    SHEPPARD, BL
    BURKE, G
    BONNAR, J
    BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 1994, 101 (11): : 1023 - 1023
  • [49] Comparison of Proton Pump Inhibitor and Histamine-2 Receptor Antagonist in the Prevention of Recurrent Peptic Ulcers/Erosions in Long-Term Low-Dose Aspirin Users: A Retrospective Cohort Study
    Chen, Wen-Chi
    Li, Yun-Da
    Chiang, Po-Hung
    Tsay, Feng-Woei
    Chan, Hoi-Hung
    Tsai, Wei-Lun
    Tsai, Tzung-Jiun
    Wang, E-Ming
    Cheng, Jin-Shiung
    Lai, Kwok-Hung
    BIOMED RESEARCH INTERNATIONAL, 2014, 2014
  • [50] MK-0966, a cyclooxygenase-2 (COX-2) specific inhibitor, had no effect on the anti-platelet activity of low-dose aspirin (ASA) measured by serum thromboxane B2 (TXB2) production and platelet aggregation.
    Greenberg, HE
    Gillen, LP
    Dorval, EP
    Wildonger, L
    Larson, P
    Huntington, M
    Wong, P
    Gottesdiener, K
    Waldman, SA
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1999, 65 (02) : 163 - 163
12345